- Over 2 million total VOQUEZNA® prescriptions filled through
October 16, 2026 - Q3 2026 net revenues of
$84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 - Generated positive operating cash flow for the second consecutive quarter
- Reaffirmed full-year 2026 financial guidance
- Conference call and webcast today,
October 29, 2026 , at8:00 a.m. EDT
“We are pleased to report continued solid revenue growth and improved operating profitability for the third quarter,” said
“Our third quarter results reflect Phathom’s significant financial transformation, with revenue growth of 71% year over year and positive cash flow from operations for the second consecutive quarter,” said
Recent Business Highlights and Third Quarter 2026 Results
VOQUEZNA Commercial Progress:
- Over 2 million total VOQUEZNA prescriptions have been filled since launch through
October 16, 2026 . After achieving the first million prescriptions just over two years into launch, Phathom reached its second million filled prescriptions less than a year later. - Approximately 380,000 total VOQUEZNA prescriptions were filled during the third quarter 2026, including approximately 248,000 covered prescriptions and 132,000 cash-pay prescriptions.
- Covered prescriptions in the third quarter amounted to approximately 65% of total quarterly prescriptions. Covered prescription volume increased approximately 19% compared to the second quarter 2026. Cash-pay prescription volume increased approximately 6% sequentially.
- Phathom implemented several initiatives designed to improve VOQUEZNA access dynamics, including its “Access First” field messaging and promotional materials, and at the end of the third quarter, the introduction of a new copay offering through Phathom’s pharmacy partner, BlinkRx, under which eligible commercially insured patients may pay as little as
$0 for VOQUEZNA.
Clinical and Regulatory Updates:
- VOQUEZNA Phase 3 As-Needed Program
- Building on previously reported positive Phase 2 results, on
September 29, 2026 , Phathom announced the initiation of pHalcon-NERD-302, a registrational Phase 3 study of VOQUEZNA for as-needed (PRN) use in Non-Erosive Gastroesophageal Reflux Disease (NERD). The first subject has been dosed, and sites are currently enrolling across theU.S . Topline results are expected in the first quarter 2028. - If successful, this Phase 3 program could support a potential label expansion for VOQUEZNA, which, if approved, could offer a differentiated treatment option and potentially expand the market opportunity for VOQUEZNA, by providing flexibility for patients with NERD to take treatment as-needed instead of chronic daily dosing.
- Building on previously reported positive Phase 2 results, on
- Eosinophilic Esophagitis (EoE)
- Phathom expects to report topline results during the fourth quarter 2026 for the 12-week blinded treatment portion of its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in patients with Eosinophilic Esophagitis (EoE).
- VOQUEZNA Data at ACG 2026
- At the
American College of Gastroenterology’s (ACG) 2026 Annual Scientific Meeting, Phathom presented new data highlighting the clinical and potential economic value of VOQUEZNA in GERD. A new predictive cost-effectiveness analysis projected VOQUEZNA to be cost-effective compared with proton pump inhibitors (PPIs) for the healing and maintenance of Erosive GERD in adults, with potential healthcare cost savings at the estimated net price based on clinical healing outcomes and fewer anticipated downstream interventions required. - Vonoprazan, the active drug in VOQUEZNA, was also the subject of 38 independent, investigator-initiated abstracts presented at ACG 2026, reflecting continued scientific interest across GERD, H. pylori eradication, and other gastrointestinal conditions.
- At the
- VOQUEZNA Regulatory Exclusivity
- On
October 26, 2026 , theU.S. District Court for the District of Columbia granted Phathom’s motion to intervene in the litigation filed byBDR Pharmaceuticals against the FDA regarding VOQUEZNA’s regulatory exclusivity. OnOctober 23, 2026 , FDA opened a public comment docket on issues raised in the litigation, with comments dueNovember 23, 2026 . - Phathom believes the FDA carefully and correctly evaluated this issue in its
June 6, 2025 decision granting Phathom’sDecember 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets throughMay 3, 2032 , as reflected in the Orange Book. Phathom intends to vigorously defend its statutory exclusivities.
- On
Third Quarter 2026 Financial Results:
- Revenue: Net revenues for the third quarter 2026 were
$84.7 million , an increase of$35.2 million compared to$49.5 million for third quarter 2025. The increase was due to continued growth from execution of Phathom’s commercial strategy. - Research and development (R&D) expenses: R&D expenses for the third quarter 2026 were
$8.7 million , an increase of$1.7 million compared to$7.0 million for third quarter 2025. The increase was primarily due to higher clinical development and regulatory costs. - Selling, general and administrative (SG&A) expenses: SG&A expenses for the third quarter 2026 were
$57.7 million , an increase of$6.1 million compared to$51.6 million for third quarter 2025. The increase was primarily due to higher promotional and personnel-related expenses. - Operating expenses: Operating expenses for the third quarter 2026 were
$66.4 million , compared to$58.6 million for third quarter 2025. The increase was primarily attributable to higher clinical development costs associated with Phathom’s ongoing and planned clinical programs, as well as increased commercial investment supporting its sales force and Access First initiatives. Third quarter 2026 operating expenses included non-cash stock-based compensation of$5.9 million , compared to$9.3 million in the prior-year period. Non-GAAP operating expenses, excluding stock-based compensation, were$60.5 million , compared to$49.3 million for third quarter 2025. - Net loss: Net loss for the third quarter 2026 was
$13.9 million , compared to$30.0 million for third quarter 2025. Non-GAAP adjusted net income for the third quarter 2026 was$3.0 million compared to a non-GAAP adjusted net loss of$11.2 million for the same period in 2025. These non-GAAP adjusted amounts, as more fully described below under “Non-GAAP Financial Measures,” exclude non-cash stock-based compensation charges, non-cash interest expense related to the accounting for our revenue interest financing liability, which is in excess of the actual interest owed, and interest expense related to the amortization of debt discount on our term loan. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. - Cash and cash equivalents: As of
September 30, 2026 , cash and cash equivalents were$184.6 million , an increase of$2.1 million compared to the second quarter endedJune 30, 2026 . Phathom continues to believe cash on hand along with anticipated future cash generated from operations will be sufficient to invest in its business and satisfy all outstanding debt obligations without requiring additional debt or equity financing.
2026 Financial Guidance
Phathom is maintaining its full-year 2026 financial guidance as follows:
| FY 2026 Guidance | |||
| Net revenue | $310–325 million | ||
| Gross-to-net discount | 55–59% | ||
| Gross margin | ~80% | ||
| Non-GAAP operating expenses, excluding stock-based compensation | $235–245 million |
Conference Call and Webcast
Phathom will host a conference call and webcast to discuss its third quarter 2026 financial results and business highlights today,
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in
Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom’s results of operations. When GAAP financial measures are viewed in conjunction with these non-GAAP financial measures, investors are provided with a more meaningful understanding of Phathom’s ongoing operating performance and are better able to compare Phathom’s performance between periods. In addition, these non-GAAP financial measures are among those indicators Phathom uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this press release.
About
Forward-Looking Statements
This press release contains forward-looking statements, including without limitation statements regarding: our guidance and expectations regarding financial results for 2026, including revenues from sales of VOQUEZNA, operating expenses, gross-to-net and gross margin; our beliefs, outlook and expectations with respect to future commercialization plans, activities and potential results; our belief in the potential size of the commercial opportunity for VOQUEZNA and ability to realize its potential; our belief in the sufficiency of our cash and expected revenues to fund our current operating plan and meet outstanding financial obligations; our development plans and potential timelines including our expectations for reporting topline results from the pHalcon-EoE-201 trial and our Phase 3 clinical trial in NERD as-needed use; our belief that the FDA correctly evaluated and recognized the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets; our intent to take appropriate actions to protect our statutory exclusivities; the expected duration of NCE exclusivity for VOQUEZNA tablets; the potential timing and outcome of the litigation filed by BDR and the second purported ANDA filer; the timing and potential impact of the FDA public docket and potential decisions the FDA may make in light of the comments received; our business strategy, goals, mission and vision, including our goal to be a leader in GI; and our other expectations, forecasts and predictions as to future performance, financial and other results and likelihood of success. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risk that: we may not be able to continue to successfully commercialize VOQUEZNA, achieve operating results, revenues or growth at the levels we expect, or realize the potential market opportunity; the market opportunity for VOQUEZNA may be significantly smaller than our expectations; market acceptance for VOQUEZNA from healthcare professionals, patients, and payors in the indications for which it is approved may be significantly lower than we anticipate; we may encounter coverage, reimbursement, market access, or other issues in the course of our commercialization efforts that may negatively impact our efforts and results; our ongoing and planned commercial activities may not have the impact on results we expect; the unmet need for new treatment options in GERD may not be as high as we anticipate; estimates of the number of patients with the disorders for which VOQUEZNA is approved, now or in the future, and our estimates of potential market size may not be accurate; our decisions as to where to allocate our resources and focus our efforts may not lead to the results we expect; BDR and the second purported ANDA filer may succeed in challenging the FDA’s recognition of the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets, which would result in a reduction in the period of regulatory exclusivity and permit the FDA to receive and potentially approve ANDAs referencing VOQUEZNA tablets earlier than currently anticipated; members of the public may comment on the FDA public docket in a manner adverse to our position, which may influence the FDA’s decision, and the FDA may, in light of those comments or otherwise, reconsider, modify or reverse its prior decision recognizing the GAIN Act extension of NCE exclusivity for VOQUEZNA tablets; the litigation, including any appeals, may be lengthy, costly and distracting to management, and its timing and outcome are uncertain; developments in the litigation or related to the FDA’s request for comments, or public perception of them, may hurt our stock price, VOQUEZNA sales, business, financial condition and prospects; we may be unsuccessful in defending our Orange Book-listed patents against challenges by third parties; we may face competition earlier than expected if we lose regulatory or patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets, including as a result of an adverse outcome in the BDR and related litigation or an adverse FDA decision; our results may be negatively impacted by the launch of other competitive products; we may experience adverse impact as the result of our dependence on third parties in connection with commercialization, product manufacturing, research and preclinical and clinical testing; we may be negatively impacted by regulatory developments or other governmental actions in
MEDIA CONTACT
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
1-877-742-8466
ir@phathompharma.com
© 2026
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK,
| Selected Condensed Balance Sheets | ||||||||||||||||
| (in thousands) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Cash and cash equivalents | $ | 184,558 | $ | 129,972 | ||||||||||||
| Total assets | $ | 345,020 | $ | 259,149 | ||||||||||||
| Total liabilities | $ | 692,659 | $ | 697,318 | ||||||||||||
| Total stockholders' deficit | $ | (347,639 | ) | $ | (438,169 | ) | ||||||||||
| Condensed Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (in thousands, except share and per share amounts) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Product revenue, net | $ | 84,722 | $ | 49,504 | $ | 217,297 | $ | 117,526 | ||||||||
| Cost of revenue | 18,367 | 6,190 | 45,458 | 14,951 | ||||||||||||
| Gross profit | 66,355 | 43,314 | 171,839 | 102,575 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 8,745 | 7,027 | 24,330 | 25,287 | ||||||||||||
| Selling, general and administrative | 57,695 | 51,558 | 167,037 | 231,346 | ||||||||||||
| Total operating expenses | 66,440 | 58,585 | 191,367 | 256,633 | ||||||||||||
| Loss from operations | (85 | ) | (15,271 | ) | (19,528 | ) | (154,058 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest income | 1,600 | 1,413 | 4,846 | 5,840 | ||||||||||||
| Interest expense | (15,387 | ) | (16,108 | ) | (46,287 | ) | (51,696 | ) | ||||||||
| Other expense, net | (25 | ) | (7 | ) | (879 | ) | (185 | ) | ||||||||
| Total other expense | (13,812 | ) | (14,702 | ) | (42,320 | ) | (46,041 | ) | ||||||||
| Net loss and comprehensive loss | $ | (13,897 | ) | $ | (29,973 | ) | $ | (61,848 | ) | $ | (200,099 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.16 | ) | $ | (0.41 | ) | $ | (0.74 | ) | $ | (2.76 | ) | ||||
| Weighted-average shares of common stock outstanding, basic and diluted | 84,892,631 | 73,396,435 | 83,573,861 | 72,615,910 | ||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures | ||||||||||||||||
| (in thousands, except share and per share amounts) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Reconciliation of GAAP to Non-GAAP adjusted net income (loss): | ||||||||||||||||
| GAAP net loss | $ | (13,897 | ) | $ | (29,973 | ) | $ | (61,848 | ) | $ | (200,099 | ) | ||||
| Stock-based compensation expense (A) | 5,921 | 9,297 | 18,167 | 23,109 | ||||||||||||
| Non-cash interest on revenue interest financing liability | 10,009 | 8,749 | 29,138 | 30,058 | ||||||||||||
| Interest expense related to amortization of debt discount | 953 | 775 | 2,709 | 2,205 | ||||||||||||
| Non-GAAP adjusted net income (loss) | $ | 2,986 | $ | (11,152 | ) | $ | (11,834 | ) | $ | (144,727 | ) | |||||
| Reconciliation of GAAP to Non-GAAP adjusted net income (loss) per share — basic and diluted: | ||||||||||||||||
| GAAP net loss per share — basic and diluted | $ | (0.16 | ) | $ | (0.41 | ) | $ | (0.74 | ) | $ | (2.76 | ) | ||||
| Stock-based compensation expense (A) | 0.07 | 0.13 | 0.22 | 0.32 | ||||||||||||
| Non-cash interest on revenue interest financing liability | 0.12 | 0.12 | 0.35 | 0.41 | ||||||||||||
| Interest expense related to amortization of debt discount | 0.01 | 0.01 | 0.03 | 0.03 | ||||||||||||
| Non-GAAP net income (loss) per share — basic and diluted | $ | 0.04 | $ | (0.15 | ) | $ | (0.14 | ) | $ | (2.00 | ) | |||||
| Weighted-average shares of common stock outstanding, basic and diluted | 84,892,631 | 73,396,435 | 83,573,861 | 72,615,910 | ||||||||||||
| (A) Stock-based compensation consists of the following: | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Research and development | 828 | 2,063 | 2,753 | 5,043 | ||||||||||||
| Selling, general and administrative | 5,093 | 7,234 | 15,414 | 18,066 | ||||||||||||
Source: